Buformin

Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al)^[1]. In Vitro: Buformin (0-10?mM; 5 days) inhibits SKBR3 and BT474 cells growth as a concentration-dependent manner, exhibits IC₅₀ values of 246.7?μM and ?98.6?μM for erbB-2-overexpressing SKBR3 and BT474 cells, respectively^[1].
Buformin (0-3 mM; 48 hours) ?increases the percentage of cells in G0/G1 phase and reduced the percentage of cells in S phase, especially in the SKBR3 cells^[1].
Buformin (0-3 mM; 24 hours) suppresses RTK activation, including erbB-2 and IGF1R signaling ?downstream, and Akt activation/phosphorylation is inhibited in both SKBR3 and BT474 cells^[1].
In Vivo: Buformin (oral administation; 7.6?mmol/kg of chow; 7 days) exhibits significantly reduced tumor volumes and weights, and?hinders mammary morphogenesis and proliferation in MMTV-erbB-2 transgenic mice^[1]